Tonix Pharmaceuticals stock halted ahead of FDA approval news
Introduction & Market Context
Codexis Inc. (NASDAQ:CDXS) presented its second-quarter 2025 financial results on August 13, 2025, revealing a substantial improvement in performance compared to both the previous quarter and the same period last year. The enzyme engineering company’s stock responded positively, trading up 4.2% in aftermarket activity to $2.98, continuing the day’s 6.64% gain during regular trading hours.
The Q2 results represent a significant recovery for Codexis following a challenging first quarter when the company missed both revenue and earnings forecasts, resulting in a 10% stock decline. The company’s shares, which hit a 52-week low of $1.90 earlier this year, have shown signs of recovery but remain well below their 52-week high of $6.08.
Quarterly Performance Highlights
Codexis reported total revenue of $15.3 million for Q2 2025, a substantial 91.25% increase from $8.0 million in Q2 2024. This performance also marks a dramatic improvement from the $7.5 million reported in Q1 2025, suggesting the company’s business has gained significant momentum.
As shown in the following financial results slide, the company also achieved notable improvements in several key metrics:
The company’s product gross margin expanded dramatically to 72% in Q2 2025, up from 45% in the same period last year, reflecting improved operational efficiency and potentially a more favorable product mix. This continues the positive trend seen in Q1, when product gross margin had improved to 55%.
Net loss per share was reduced to $0.16, half of the $0.32 loss reported in Q2 2024 and better than the $0.25 loss reported in Q1 2025. This improvement came despite a 21.1% increase in R&D expenses, which rose to $13.8 million as the company continued to invest in its technology platforms.
Detailed Financial Analysis
Codexis made significant progress in reducing its operating loss, which narrowed to $12.9 million in Q2 2025 from $22.7 million in the same period last year, representing a 43.2% improvement. This was achieved through both revenue growth and cost management initiatives.
The company’s SG&A expenses decreased by 21.7% year-over-year to $12.3 million, while cost of product revenue fell to $2.1 million from $3.5 million in Q2 2024, despite the higher sales volume. These improvements suggest effective cost control measures and potential economies of scale.
In its presentation, Codexis highlighted the quarter’s strong performance and building momentum across its business segments:
Management noted that the company has strengthened its balance sheet with "targeted, right-sized financing," which should provide additional runway as it continues to develop its ECO Synthesis platform. The company also emphasized its reduced cash burn rate compared to the previous year, addressing a key concern highlighted in Q1 results when cash burn was flagged as a significant issue.
Strategic Initiatives
Codexis is pursuing a dual-track strategy with its two core business segments: Pharma Biocatalysis and ECO Synthesis. The company described its Pharma Biocatalysis business as a profitable "business within a business" that helps fund the development of its newer ECO Synthesis platform.
The presentation detailed progress across both business segments:
In the Pharma Biocatalysis segment, Codexis reported recent wins with large pharmaceutical companies that are expected to provide a foundation for future revenue growth. The company emphasized that customers continue to bring their most complex manufacturing challenges to Codexis, suggesting strong industry recognition of its technological capabilities.
For the ECO Synthesis platform, which focuses on enzymatic RNA synthesis, Codexis reported continued expansion of its ligase business and increased customer interest following the TIDES US meeting. The company now has 34 ongoing customer engagements for ECO Synthesis, indicating growing market traction. Management also noted that they are exploring the possibility of establishing a Codexis-owned GMP facility, which would represent a significant expansion of their manufacturing capabilities.
Forward-Looking Statements
Despite the strong quarterly performance, Codexis maintained its 2025 revenue guidance range, which had been set at $64-68 million following Q1 results. This guidance range had been lower than analyst expectations at that time.
The company cautioned investors about the potential for continued "lumpiness" in quarter-to-quarter revenue as ECO Synthesis revenues grow, suggesting that the dramatic improvement seen in Q2 may not necessarily indicate a smooth upward trajectory for future quarters.
Codexis management emphasized that the company is shifting emphasis to newer assets with longer runway and better economics, particularly in the ECO Synthesis platform. The company’s focus on chemo-enzymatic routes in siRNA manufacturing appears to be gaining traction, with management noting increased customer interest following dissatisfaction with other ligases.
The recovery demonstrated in Q2 2025 represents a significant turnaround from the disappointing Q1 results, but Codexis will need to maintain this momentum to achieve its full-year guidance and convince investors of its long-term growth potential in the competitive enzyme engineering and RNA synthesis markets.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.